EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Bioquell Asia Pacific,
Managing Director
Bioquell Asia Pacific based in Singapore in April to be the regional office for our activities in Asia and Australasia I am responsible for the development of our business throughout the region and for the success and profitability of our activities We provide equipment and services for environmental biodecontamination across the pharmaceutical therapeutic development
Articles
Alpha-fetoprotein as a Shuttle for Medicines
Pregnancy is a natural phenomenon that ensures the survival of the species The suppression of the immune response in pregnancy is robust since the embryo cells have half the fathers proteins that should be recognised by the mothers immune system as foreign Even surrogate motherhood is possible with no genetic relationship to the embryo at all The embryo cell is turning
Research Insights
Validated Spectrometric Determination Of Penciclovir And Entecavir In Bulk And In Pharmaceutical Preparations
Abstract Simple rapid and sensitive spectroscopic methods were developed and validated for the determination of antiviral agents namely penciclovir PCV and entecavir ETV The first method is based on measuring the native fluorescence of each of the cited drugs at its optimum excitation and emission wavelengths The fluorescence intensity was measured for PCV
Case Studies
Remarkable Regression Of A Giant Cell Tumor Of The Cervical Spinetreated Conservatively With Denosumab: A Case Study
Abstract This case study has been conducted to establish the fact that Denosumab can be used as an adjuvant therapy by which to avoid or reduce the risks and morbidity of surgical treatment in patients with spinal GCTs extending into the nearby tissues considering the adequate duration safety and lack of adverse events of this treatment even though further
Techno Trends
Daiichi Sankyo and Merck Introduce Breakthrough Ifinatamab Deruxtecan for the Treatment of ES-Small Cell Lung Cancer
Daiichi Sankyo and Merck have introduced ifinatamab deruxtecan as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of adult patients with pretreated extensivestage small cell lung cancer ESSCLC
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
3D Printing Revolutionising Nanotechnology
Mansi Athalye is Assistant Professor in Department of Pharmaceutics at L. M. College of Pharmacy, India with approx. 10 years of teaching and research experience. She has published 12 papers in international and national journals and has presented 22 papers in various conferences as author and co-author with 1 Indian Patent granted in 2018.
Sagar Popat is research student pursuing M. Pharmacy in Pharmaceutics at L. M. College of Pharmacy. He has worked on the topic ‘Cataract of goat eye lens by Invitro and Ex-vivo method’. He has published 1 research article and has won 1st prize in oral presentation at national level conference.
Biologics at Scale
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Personalized Therapeutics program, focusing on next-generation modalities and precision medicine. Her expertise spans market analytics, forecasting, and competitive benchmarking, supporting strategic decision-making for global clients. Recognised as a trusted growth advisor, helping stakeholders navigate disruption, accelerate innovation, and capture transformative growth opportunities across the evolving biopharma landscape.
Peptide-Drug Conjugates in Precision Oncology
Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.
Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.
Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.
Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”
Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.
APAC’s Rising Role in Neurodegenerative Disease Research and Development
Simona Lambertini is a senior global clinical research leader with nearly 20 years of experience in international clinical development, research strategy and stakeholder engagement. She has led complex multicountry programs across Europe, North America and the Middle East, collaborating with pharma, biotech and research institutions across high-complexity therapeutic areas.
Covid -19 and Nanoparticles
Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow a very prestigious fellowship of Latin America at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, Brazil.
Deepika has completed here master degree from Department of Biotechnology, Deenbandhu Choturam University and Technology, Sonepat, Haryana, India.
Reshma completed her master's degree from the Royal Global University in Guwahati, Assam, India's department of Biotechnology.
Neehasri holds a master's degree in Zoology from Gauhati University in Guwahati, Assam, India, and has also passed the B.Ed. professional exam.
press releasesRead more...
Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea (aflibercept), in Canada
Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and Samsung Bioepis Co Ltd today announced that the companies have entered into a license and commercialization agreement for OPUVIZ aflibercept
WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
WuXi Biologics HK a leading global Contract Research Development and Manufacturing Organization CRDMO announced that its MFG drug substance manufacturing facility located in Hebei
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
Everest Medicines HKEX HK announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics Inc NASDAQ TVTX for the development
Fischer Medical Ventures Highlights Strategic Partnership as NYB.AI Showcased at NVIDIA GTC Taiwan 2026
Fischer Medical Ventures Limited FMVL today announced that its strategic partner Nanyang Biologics has achieved a significant international milestone with its AIpowered molecular research platform NYBAI
RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers
RoslinCT a leading global cell therapy Contract Development and Manufacturing Organization today announced a strategic partnership with BlueRock Therapeutics a leader in stem cell therapeutic development
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations
Merck a leading science and technology company today announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active
EventsRead more...
16 - 19
Jul 2026Bio Asia Taiwan 2026
Taipei Nangang Exhibition Cent...
20 - 22
Jul 20266th mRNA-Based Therapeutics Summit
The Westin Boston Seaport Dist...
20 - 22
Jul 2026Liquid Biopsy for Precision Oncology Summit
Boston, MA, USA
24 - 25
Jul 2026Cardiovascular Medicine Pharmacology 2026
Paris, France
26 - 30
Jul 2026ADLM 2026
Anaheim, CA USA
27 - 28
Jul 2026Pharmacovigilance & Drug Safety 2026
Rome, Italy
27 - 28
Jul 2026Pharmacology 2026
Rome, Italy
27 - 28
Jul 2026PharmaSci Innovations 2026
Rome, Italy
LATEST NEWSRead more...
Samsung Bioepis Enters into Agreement with Proteina for AI-Based Antibody Therapeutics Development
Samsung Bioepis has entered into a licence agreement with Proteina to collaborate on a governmentsupported national research and development RD initiative focused on developing artificial intelligence AIbased antibody therapeutics
Teva Enters into Agreement with Polpharma Biologics for Ocrelizumab Biosimilar Candidate
Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement under which Teva will receive exclusive rights to commercialise both intravenous and subcutaneous formulations
Evogene and Tel Aviv University Launch AI-Driven Small-Molecule Drug Discovery Initiative
Evogene has entered into a strategic collaboration with the Blavatnik Center for Drug Discovery BCDD at Tel Aviv University to accelerate AIdriven smallmolecule drug discovery
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
Certara Inc a global leader in modelinformed drug development is partnering with NVIDIA to advance Certaras open integrated AI platform unifying its scientific software regulatory expertise and proprietary datasets
Bayer Enters into Partnership with University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado to Advance Drug Development and Clinical Trials
Bayer has formed a strategic partnership with the University of Colorado Anschutz UCHealth and Childrens Hospital Colorado to strengthen clinical research and accelerate drug development
OTR Therapeutics Enters into Collaboration with LG Chem to Advance Oncology Drug Development
OTR Therapeutics has entered into a strategic collaboration with LG Chem to identify evaluate and develop innovative oncology therapies originating from China The partnership aims to accelerate the development of promising cancer treatments